G

Getwell Hospital & Research Institute | Research Site

Research site
(Unclaimed)
Location
20/1, Dr, Khare Marg, Dhantoli, Nagpur, Maharashtra, India

Site insights

Top conditions

Top treatments

Durvalumab
Paclitaxel
Pembrolizumab
Capivasertib
Dapagliflozin
Saxagliptin
AZD9833
Nintedanib
Brazikumab
Camizestrant

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

23 of 61 total trials

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (SERENA-4)

The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor)...

Active, not recruiting
ER-Positive HER2-Negative Breast Cancer
Drug: Luteinizing hormone-releasing hormone (LHRH) agonist
Drug: AZD9833 placebo

The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared...

Enrolling
Metastatic Non-small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Pemetrexed

This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalum...

Enrolling
Breast Cancer
Drug: Epirubicin
Drug: Olaparib

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without du...

Enrolling
Breast Cancer
Drug: Paclitaxel
Drug: Dato-DXd

This is a multicentre, randomised, double-blind (DB), parallel-group, placebo-controlled, 24-week Phase III study to compare the efficacy and safety...

Enrolling
Hypereosinophilic Syndrome
Biological: Placebo
Biological: Benralizumab

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - e...

Enrolling
Breast Cancer, Early Breast Cancer
Drug: Anastrozole
Drug: Exemestane

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...

Enrolling
Breast Cancer
Drug: Carboplatin
Drug: Nab-paclitaxel

A Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 given by subcutaneous injection in adult participants with non-cirrhotic non-alc...

Active, not recruiting
Nonalcoholic Steatohepatitis
Other: Placebo
Drug: AZD2693

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER...

Enrolling
Breast Cancer, Early Breast Cancer
Drug: Exemestane
Drug: Letrozole

A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormon...

Enrolling
Locally Advanced (Inoperable) or Metastatic Breast Cancer
Drug: Palbociclib
Drug: Capivasertib

This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) ve...

Active, not recruiting
Hormone-Sensitive Prostate Cancer
Drug: Capivasertib
Other: Placebo

Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Tri...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Capivasertib
Drug: Placebo

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by mainte...

Active, not recruiting
Endometrial Neoplasms
Biological: durvalumab
Drug: olaparib

The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult...

Enrolling
Chronic Obstructive Pulmonary Disease (COPD)
Drug: Tozorakimab
Drug: Placebo

The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab administered subcutaneously (SC) in adult participants with...

Enrolling
Chronic Obstructive Pulmonary Disease (COPD)
Drug: Placebo
Drug: Tozorakimab

A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients wit...

Enrolling
Hepatocellular Carcinoma
Procedure: Transarterial Chemoembolization (TACE)
Drug: Lenvatinib

Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo co...

Enrolling
Chronic Obstructive Pulmonary Disease (COPD)
Combination Product: Tozorakimab 1
Combination Product: Tozorakimab 2

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with...

Enrolling
Non-Small Cell Lung Cancer
Drug: Datopotamab Deruxtecan
Drug: Rilvegostomig

The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA...

Enrolling
Metastatic Castration-Sensitive Prostate Cancer
Drug: Abiraterone Acetate
Drug: Placebo

This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tre...

Active, not recruiting
Metastatic Urothelial Cancer
Unresectable Locally Advanced Urothelial Cancer
Drug: Carboplatin + Gemcitabine
Drug: Durvalumab

Trial sponsors

AstraZeneca logo
Amgen logo
Biogen logo
Boehringer Ingelheim logo
G
Lilly logo
N

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems